FDA inspection
Amneal Pharmaceuticals of New York, LLC: FDA inspection ending Apr 18, 2007
FDA inspection 469041 · Voluntary Action Indicated (VAI) · Hauppauge, NY
Key facts
| Inspection ID | 469041 |
|---|---|
| Firm | Amneal Pharmaceuticals of New York, LLC |
| FEI number | 2434153 |
| Address | 75 Adams Ave |
| City | Hauppauge |
| State | NY |
| ZIP | 11788-3605 |
| Fiscal year | 2007 |
| Inspection end date | Apr 18, 2007 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data